Vanta Bioscience (BOM:540729) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 07, 2026)


BOM:540729 Vanta Bioscience Ltd BOM:540729
56 GF Score
Price ₹25.29
GF Value ₹12.07
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Vanta Bioscience Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Vanta Bioscience's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

BOM:540729 vs TMO, DHR, IDXX: Margin of Safety % (DCF FCF Based) Comparison

For the Diagnostics & Research subindustry, Vanta Bioscience's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vanta Bioscience Margin of Safety % (DCF FCF Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Vanta Bioscience's Margin of Safety % (DCF FCF Based) falls into.


BOM:540729
56GF Score
Vanta Bioscience Ltd BOM:540729
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vanta Bioscience (BOM:540729) Overvalued in 2026?

Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued. The current stock price of ₹25.29 is trading 109.5% above its estimated GF Value™ of ₹12.07. GuruFocus considers Vanta Bioscience to be Significantly Overvalued.

Key valuation signals for BOM:540729:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: ₹12.07 vs. price of ₹25.29 (109.5% above fair value)
  • GF Score™: 56/100 with 10 warning signs

No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanta Bioscience Business Description

Address No. 02/G/308/G, Umajay Complex, No. 3/FF/SF/1-20-248, Rasoolpura, Secunderabad, TG, IND, 500003
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
56GF Score

Get the complete analysis for BOM:540729

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹25.29
Price
₹12.07
GF Value